Press "Enter" to skip to content

Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer – GlobeNewswire

admin 0

Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer  GlobeNewswire

Initiation of Phase 1 Trial expected in the third quarter of 2019. – ARV-471 will be Arvinas’ second targeted PROTAC® protein degrader to enter the clinic.

“breast cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *